EQT Partners has sold Swedish point-of-care patient testing company HemoCue to Quest Diagnostics Inc. (NYSE: DGX) for approximately $420 million in cash. www.hemocue.se < ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
EQT Partners has sold Swedish point-of-care patient testing company HemoCue to Quest Diagnostics Inc. (NYSE: DGX) for approximately $420 million in cash. www.hemocue.se < ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
Copyright PEI Media
Not for publication, email or dissemination